MX2022005850A - Inmunoglobulinas modificadas para seleccionar depositos de amiloide como objetivo. - Google Patents
Inmunoglobulinas modificadas para seleccionar depositos de amiloide como objetivo.Info
- Publication number
- MX2022005850A MX2022005850A MX2022005850A MX2022005850A MX2022005850A MX 2022005850 A MX2022005850 A MX 2022005850A MX 2022005850 A MX2022005850 A MX 2022005850A MX 2022005850 A MX2022005850 A MX 2022005850A MX 2022005850 A MX2022005850 A MX 2022005850A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- amyloid
- methods
- peptide fusion
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
Abstract
Se proporcionan en la presente inmunoglobulinas modificadas que comprenden un péptido reactivo a amiloide unido a un anticuerpo, así como también anticuerpos humanizados que se unen a fibrillas amiloides humanas y proteínas de fusión anticuerpo-péptido. También se proporcionan en la presente métodos para tratar enfermedades de base amiloide mediante la administración de una inmunoglobulina modificada, anticuerpo humanizado o proteína de fusión anticuerpo-péptido.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962936002P | 2019-11-15 | 2019-11-15 | |
US202063074912P | 2020-09-04 | 2020-09-04 | |
PCT/US2020/060596 WO2021097360A1 (en) | 2019-11-15 | 2020-11-13 | Modified immunoglobulins for targeting amyloid deposits |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022005850A true MX2022005850A (es) | 2022-08-15 |
Family
ID=75912899
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022005850A MX2022005850A (es) | 2019-11-15 | 2020-11-13 | Inmunoglobulinas modificadas para seleccionar depositos de amiloide como objetivo. |
Country Status (11)
Country | Link |
---|---|
US (2) | US20220411489A1 (es) |
EP (1) | EP4058479A4 (es) |
JP (1) | JP2023502968A (es) |
KR (1) | KR20220113950A (es) |
CN (1) | CN115298214A (es) |
AU (1) | AU2020385183A1 (es) |
BR (1) | BR112022009273A2 (es) |
CA (1) | CA3158206A1 (es) |
IL (1) | IL292903A (es) |
MX (1) | MX2022005850A (es) |
WO (1) | WO2021097360A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2023553877A (ja) * | 2020-12-04 | 2023-12-26 | ユニバーシティ オブ テネシー リサーチ ファウンデーション | アミロイド疾患を診断する方法 |
WO2022236286A1 (en) * | 2021-05-05 | 2022-11-10 | University Of Tennessee Research Foundation | Peptide-fc fusions for treating amyloid disorders |
WO2022246433A1 (en) * | 2021-05-18 | 2022-11-24 | University Of Tennessee Research Foundation | Antibody-peptide fusion proteins for treating amyloid disorders |
CA3231073A1 (en) * | 2021-09-14 | 2023-03-23 | Michael Spector | Method of treating multiple myeloma |
WO2023220234A1 (en) * | 2022-05-11 | 2023-11-16 | Alexion Pharmaceuticals, Inc. | High sensitivity biotinylated peptide binding elisa assay |
WO2024050478A1 (en) * | 2022-09-02 | 2024-03-07 | University Of Tennessee Research Foundation | Chimeric antigen receptors for removal of amyloid |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
JPH09506262A (ja) * | 1993-12-08 | 1997-06-24 | ジェンザイム・コーポレイション | 特異的抗体の製造方法 |
NZ507727A (en) * | 1998-05-21 | 2003-11-28 | Univ Tennessee Res Foundation | Methods for amyloid removal using anti-amloid antibodies |
US7312318B2 (en) * | 2002-03-01 | 2007-12-25 | Immunomedics, Inc. | Internalizing anti-CD74 antibodies and methods of use |
WO2008091954A2 (en) * | 2007-01-23 | 2008-07-31 | Xencor, Inc. | Optimized cd40 antibodies and methods of using the same |
WO2016032949A1 (en) * | 2014-08-26 | 2016-03-03 | University Of Tennessee Research Foundation | Targeting immunotherapy for amyloidosis |
CA3067597C (en) * | 2017-06-29 | 2023-03-21 | The Trustees Of Columbia University In The City Of New York | Chimeric antibodies for treatment of amyloid deposition diseases |
-
2020
- 2020-11-13 AU AU2020385183A patent/AU2020385183A1/en active Pending
- 2020-11-13 MX MX2022005850A patent/MX2022005850A/es unknown
- 2020-11-13 KR KR1020227019864A patent/KR20220113950A/ko unknown
- 2020-11-13 IL IL292903A patent/IL292903A/en unknown
- 2020-11-13 JP JP2022528305A patent/JP2023502968A/ja active Pending
- 2020-11-13 CA CA3158206A patent/CA3158206A1/en active Pending
- 2020-11-13 US US17/776,827 patent/US20220411489A1/en not_active Abandoned
- 2020-11-13 BR BR112022009273A patent/BR112022009273A2/pt unknown
- 2020-11-13 CN CN202080092570.1A patent/CN115298214A/zh active Pending
- 2020-11-13 EP EP20887541.9A patent/EP4058479A4/en active Pending
- 2020-11-13 WO PCT/US2020/060596 patent/WO2021097360A1/en unknown
-
2023
- 2023-03-09 US US18/181,489 patent/US20230265178A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL292903A (en) | 2022-07-01 |
CA3158206A1 (en) | 2021-05-20 |
EP4058479A1 (en) | 2022-09-21 |
US20230265178A1 (en) | 2023-08-24 |
JP2023502968A (ja) | 2023-01-26 |
EP4058479A4 (en) | 2024-02-28 |
WO2021097360A1 (en) | 2021-05-20 |
CN115298214A (zh) | 2022-11-04 |
BR112022009273A2 (pt) | 2022-10-04 |
US20220411489A1 (en) | 2022-12-29 |
KR20220113950A (ko) | 2022-08-17 |
AU2020385183A1 (en) | 2022-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022005850A (es) | Inmunoglobulinas modificadas para seleccionar depositos de amiloide como objetivo. | |
PE20231067A1 (es) | Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos | |
EA201992755A1 (ru) | Новые моноклональные антитела к белку 4, ассоциированному с цитотоксическими т-лимфоцитами, (ctla-4) | |
AR126019A1 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
EA201290525A1 (ru) | Новые антитела-антагонисты, их fab-фрагменты против gpvi и способы их применения | |
EA200970879A1 (ru) | Связывающие белки, включающие антитела, производные антител и фрагменты антител, которые специфически связываются с cd154, и их применения | |
EA201792221A1 (ru) | Антитела против сортилина и способы их применения | |
AR091605A1 (es) | Proteinas de union anti-mesotelina | |
EA201790342A1 (ru) | Антитела к trem2 и способы их применения | |
WO2017060322A3 (en) | Ptefb-inhibitor-adc | |
HRP20150934T1 (hr) | Djelovanje na abcb5 u terapiji raka | |
EP2352523A4 (en) | IMPROVED ANTI-CD19 ANTIBODIES | |
PE20120899A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b | |
RU2015144105A (ru) | Антитела к гепсидину и их применения | |
WO2011002968A3 (en) | Polypeptides and method of treatment | |
EA201691779A1 (ru) | Антитела, специфические к рецептору инсулиноподобного фактора роста 1, и их применения | |
EA202190138A1 (ru) | Анти-sirp-бета1 антитела и способы их использования | |
EA202190183A1 (ru) | Антитела к siglec-5 и способы их применения | |
MX2021012997A (es) | Anticuerpos anti-c5 humanizados bifuncionales y proteínas de fusión del factor h y usos de los mismos. | |
BR112022009317A2 (pt) | Anticorpos de cd73 biparatópicos | |
MX2022001260A (es) | Anticuerpos anti-ms4a4a y metodos de uso de los mismos. | |
MX2021015212A (es) | Anticuerpos antisortilina para uso en terapia. | |
PH12020551648A1 (en) | Human neuregulin-1 (nrg-1) recombinant fusion protein compositions and methods of use thereof | |
AU2018281871A1 (en) | Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins | |
EA202092595A1 (ru) | Антитела к siglec-7 и способы их применения |